Clinical Trial ProgressThe Phase 3 ACTION study for ONC201 is progressing, with an increasing number of study sites and patient enrollment expected to accelerate.
Market PotentialThere's a significant market potential for ONC201, targeting approximately 7,000 patients annually across key global markets with no proven effective therapies currently available.
Regulatory AdvancementDordaviprone (ONC201) received Fast Track Designation from the FDA for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, indicating regulatory support and potential for expedited development.